Liraglutide cardioprotective in high-risk Type 2 diabetes patients

Findings of the LEADER trial show that liraglutide treatment may confer a reduced risk of cardiovascular events in patients with Type 2 diabetes and a high vascular risk.
Source: MedWire News - Category: Consumer Health News Tags: Diabetes Source Type: news